DrugCite
Search

ONCOVIN

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Oncovin Adverse Events Reported to the FDA Over Time

How are Oncovin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Oncovin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Oncovin is flagged as the suspect drug causing the adverse event.

Most Common Oncovin Adverse Events Reported to the FDA

What are the most common Oncovin adverse events reported to the FDA?

Febrile Neutropenia
1652 (2.86%)
Neutropenia
1162 (2.01%)
Pyrexia
1007 (1.74%)
Pneumonia
653 (1.13%)
Sepsis
648 (1.12%)
Infection
549 (.95%)
Anaemia
547 (.95%)
Diarrhoea
535 (.93%)
Vomiting
531 (.92%)
Hypotension
493 (.85%)
Thrombocytopenia
493 (.85%)
Show More Show More
Mucosal Inflammation
451 (.78%)
White Blood Cell Count Decreased
429 (.74%)
Nausea
422 (.73%)
Pancytopenia
414 (.72%)
Septic Shock
407 (.7%)
Platelet Count Decreased
375 (.65%)
Respiratory Failure
366 (.63%)
Abdominal Pain
364 (.63%)
Pleural Effusion
341 (.59%)
Dyspnoea
337 (.58%)
Dehydration
334 (.58%)
Haemoglobin Decreased
315 (.54%)
Death
303 (.52%)
Pneumocystis Jiroveci Pneumonia
299 (.52%)
General Physical Health Deteriorati...
294 (.51%)
Fatigue
277 (.48%)
Renal Failure
275 (.48%)
Myelodysplastic Syndrome
268 (.46%)
Leukopenia
258 (.45%)
Asthenia
254 (.44%)
Deep Vein Thrombosis
251 (.43%)
Multi-organ Failure
251 (.43%)
Renal Failure Acute
249 (.43%)
Acute Myeloid Leukaemia
245 (.42%)
Neutrophil Count Decreased
244 (.42%)
Interstitial Lung Disease
237 (.41%)
Hepatitis B
236 (.41%)
Alanine Aminotransferase Increased
235 (.41%)
Convulsion
231 (.4%)
Constipation
230 (.4%)
Bone Marrow Failure
228 (.39%)
Neuropathy Peripheral
225 (.39%)
Headache
224 (.39%)
Pulmonary Embolism
220 (.38%)
Stomatitis
202 (.35%)
Ascites
193 (.33%)
Aspartate Aminotransferase Increase...
191 (.33%)
Drug Toxicity
191 (.33%)
Hyperglycaemia
190 (.33%)
Hepatic Failure
189 (.33%)
Tumour Lysis Syndrome
189 (.33%)
Febrile Bone Marrow Aplasia
187 (.32%)
Disease Progression
184 (.32%)
Tachycardia
178 (.31%)
Gastrointestinal Haemorrhage
177 (.31%)
Progressive Multifocal Leukoencepha...
173 (.3%)
Blood Bilirubin Increased
172 (.3%)
Hyponatraemia
169 (.29%)
Hypoxia
168 (.29%)
Respiratory Distress
168 (.29%)
Weight Decreased
168 (.29%)
Staphylococcal Infection
167 (.29%)
Thrombosis
167 (.29%)
Hypertension
166 (.29%)
Disseminated Intravascular Coagulat...
160 (.28%)
Neurotoxicity
160 (.28%)
Cough
158 (.27%)
Atrial Fibrillation
157 (.27%)
Acute Respiratory Distress Syndrome
153 (.26%)
Hypokalaemia
153 (.26%)
Neutropenic Sepsis
152 (.26%)
Confusional State
151 (.26%)
Encephalopathy
151 (.26%)
Blood Culture Positive
149 (.26%)
Renal Impairment
148 (.26%)
Malignant Neoplasm Progression
141 (.24%)
Chills
140 (.24%)
Cardiac Arrest
138 (.24%)
Drug Ineffective
136 (.24%)
Cardiac Failure
135 (.23%)
Leukoencephalopathy
132 (.23%)
Agranulocytosis
131 (.23%)
Osteonecrosis
129 (.22%)
Herpes Zoster
128 (.22%)
Reversible Posterior Leukoencephalo...
127 (.22%)
Haemorrhage
126 (.22%)
Hyperbilirubinaemia
126 (.22%)
Coagulopathy
125 (.22%)
Chest Pain
124 (.21%)
Cytomegalovirus Infection
124 (.21%)
Candidiasis
123 (.21%)
Off Label Use
123 (.21%)
Lymphopenia
121 (.21%)
Dizziness
120 (.21%)
Stem Cell Transplant
120 (.21%)
Back Pain
119 (.21%)
Malaise
119 (.21%)
Hepatic Function Abnormal
116 (.2%)
Pain
115 (.2%)
Liver Disorder
113 (.2%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Oncovin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Oncovin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Oncovin

What are the most common Oncovin adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Oncovin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Oncovin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Oncovin According to Those Reporting Adverse Events

Why are people taking Oncovin, according to those reporting adverse events to the FDA?

Diffuse Large B-cell Lymphoma
2604
Non-hodgkins Lymphoma
1806
Acute Lymphocytic Leukaemia
1746
B-cell Lymphoma
1116
Lymphoma
713
Multiple Myeloma
618
Show More Show More
Hodgkins Disease
573
Drug Use For Unknown Indication
478
Burkitts Lymphoma
422
Mantle Cell Lymphoma
404
Product Used For Unknown Indication
301
Chemotherapy
256
Rhabdomyosarcoma
244
T-cell Lymphoma
215
Chronic Lymphocytic Leukaemia
185
Peripheral T-cell Lymphoma Unspecif...
130
Ewings Sarcoma
123
B Precursor Type Acute Leukaemia
108
Neuroblastoma
91
Adult T-cell Lymphoma/leukaemia
80
Malignant Lymphoid Neoplasm
75
T-cell Type Acute Leukaemia
75
Nephroblastoma
72
Medulloblastoma
69
Sarcoma Metastatic
66
Sarcoma
65
Chronic Myeloid Leukaemia
54
Retinoblastoma
52
Neoplasm Malignant
52
Central Nervous System Lymphoma
51
B-cell Type Acute Leukaemia
44
Acute Myeloid Leukaemia
43
Glioma
41
Precursor T-lymphoblastic Lymphoma/...
38
Choriocarcinoma
36
Lymphocytic Leukaemia
35
Breast Cancer
35
Idiopathic Thrombocytopenic Purpura
34
Primary Mediastinal Large B-cell Ly...
33
Epstein-barr Virus Associated Lymph...
31
Non-hodgkins Lymphoma Stage Iv
30
Leukaemia
30
Primitive Neuroectodermal Tumour
30
Waldenstroms Macroglobulinaemia
28
Diffuse Large B-cell Lymphoma Stage...
28
Brain Neoplasm Malignant
28
Non-hodgkins Lymphoma Unspecified H...
28
Burkitts Leukaemia
27
Lymphoproliferative Disorder
26
Drug Exposure During Pregnancy
26
Extranodal Marginal Zone B-cell Lym...
24

Oncovin Case Reports

What Oncovin safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Oncovin. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Oncovin.